Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Bhaskar Anand Biography and Net Worth

CAO of Reata Pharmaceuticals

Bhaskar is Chief Accounting Officer at Reata Pharmaceuticals and oversees accounting & reporting, taxation, global alliances, corporate communications, and investor relations. Prior to joining Reata, Mr. Anand served as Corporate Controller of JUUL Labs, where he led the global expansion from less than $500M to a multibillion-dollar business. Prior to that, Mr. Anand also served as Head of technical accounting and SEC reporting at Oracle and was a key member of the M&A and Business Development teams that successfully acquired 20 SaaS companies in two years including the acquisition of NetSuite for $10B. He started his career at PwC where he worked for more than a decade servicing client across various industries. Mr. Anand has over 20 years of finance leadership experience. He is a CPA from California and Chartered Accountant from the Institute of Chartered Accountants of India.

What is Bhaskar Anand's net worth?: The estimated net worth of Bhaskar Anand is at least $4.29 million as of June 14th, 2023. Mr. Anand owns 24,898 shares of Reata Pharmaceuticals stock worth more than $4,291,419 as of April 28th. This net worth evaluation does not reflect any other investments that Mr. Anand may own. Learn More about Bhaskar Anand's net worth.
How old is Bhaskar Anand?: Mr. Anand is currently 45 years old. There are 5 older executives and no younger executives at Reata Pharmaceuticals. The oldest executive at Reata Pharmaceuticals is Mr. Michael D. Wortley, Exec. VP and Chief Legal & Compliance Officer, who is 75 years old. Learn More on Bhaskar Anand's age.
How do I contact Bhaskar Anand?: The corporate mailing address for Mr. Anand and other Reata Pharmaceuticals executives is 5320 LEGACY DRIVE, PLANO TX, 75024. Reata Pharmaceuticals can also be reached via phone at (972) 865-2219 and via email at [email protected]. Learn More on Bhaskar Anand's contact information.
Has Bhaskar Anand been buying or selling shares of Reata Pharmaceuticals?: Bhaskar Anand has not been actively trading shares of Reata Pharmaceuticals in the last ninety days. Most recently, Bhaskar Anand sold 2,343 shares of the business's stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $102.11, for a transaction totalling $239,243.73. Following the completion of the sale, the chief accounting officer now directly owns 24,898 shares of the company's stock, valued at $2,542,334.78. Learn More on Bhaskar Anand's trading history.
Who are Reata Pharmaceuticals' active insiders?: Reata Pharmaceuticals' insider roster includes Bhaskar Anand (CAO), Dawn Bir (Chief Commercial Officer), Elaine Castellanos (CAO), Samina Khan (SVP), Andrea Loewen (SVP), Colin Meyer (Insider), Shamim Ruff (Director), Manmeet Soni (CFO), and Michael Wortley (Insider). Learn More on Reata Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Reata Pharmaceuticals?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 236,092 shares worth more than $31,588,041.37. The most recent insider tranaction occured on September, 14th when SVP Andrea Loewen sold 3,175 shares worth more than $546,195.25. Insiders at Reata Pharmaceuticals own 26.8% of the company. Learn More about insider trades at Reata Pharmaceuticals.
Information on this page was last updated on 9/14/2023.

Bhaskar Anand Insider Trading History at Reata Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2023	Sell	2,343	$102.11	$239,243.73	24,898
3/7/2023	Sell	165	$84.58	$13,955.70	26,765
3/3/2023	Sell	820	$87.47	$71,725.40	26,930

Bhaskar Anand Buying and Selling Activity at Reata Pharmaceuticals

Reata Pharmaceuticals Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Today's Range

Now: $172.36

$172.32

$172.46

50 Day Range

MA: $171.30

$168.70

$172.36

2 Week Range

Now: $172.36

$21.83

$172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years

From Banyan Hill Publishing | Ad

If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)

Watch my video for all of the details

Bhaskar Anand Biography and Net Worth

What is Bhaskar Anand's net worth?

How old is Bhaskar Anand?

How do I contact Bhaskar Anand?

Has Bhaskar Anand been buying or selling shares of Reata Pharmaceuticals?

Who are Reata Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Reata Pharmaceuticals?